Duality Biologics Signs Exclusive Option Agreement with GSK for ADC Candidate DB-1324 in Gastrointestinal Cancer

 Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjuga...

December 04, 2024 | Wednesday | News
Merck’s Sacituzumab Tirumotecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug...

December 04, 2024 | Wednesday | News
Red Ginseng Shown to Boost Bone and Intestinal Health, Michigan State Study Reveals

Professor Narayanan Parameswaran's team at the Department of Physiology at Michigan State University announced the results of a study that s...

November 12, 2024 | Tuesday | News
Akeso Biopharma Initiates Phase III Study for Ivonescimab in Advanced Biliary Tract Cancer

Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, control...

November 01, 2024 | Friday | News
Antengene Secures South Korean Approval for XPOVIO® in Combination Therapy for Multiple Myeloma

SHANGHAI and HONG KONG, Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmac...

October 18, 2024 | Friday | News
Nuance Pharma Expands Bentrio® Nasal Spray Reach Across East and South East Asia

Altamira Therapeutics announces the extension of its exclusive license with Nuance Pharma to cover Singapore, Malaysia, Thailand, Philippines, Indonesia,...

September 17, 2024 | Tuesday | News
HUTCHMED Voluntarily Withdraws Supplemental NDA for Fruquintinib in China, Cites Need for Further Evaluation in Gastric Cancer Treatment

HUTCHMED announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination w...

August 30, 2024 | Friday | News
BioArctic AB’s Partner Eisai Announces Approval of Leqembi® (樂意保®) for Alzheimer’s Disease Treatment in Hong Kong

BioArctic AB  is pleased to announce that its partner, Eisai, has received approval from the Department of Health in Hong Kong for Leqembi® (bra...

July 11, 2024 | Thursday | News
Shanghai Junshi Biosciences' Toripalimab NDA Accepted by Hong Kong DO for Groundbreaking Nasopharyngeal Carcinoma Treatment

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...

April 25, 2024 | Thursday | News
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte and China Medical System Holdings Limited  are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...

April 02, 2024 | Tuesday | News
Biocytogen Pharmaceuticals Announces Antibody Evaluation and Option Agreement with Gilead Sciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315)  announces an antibody evaluation and option agreement with Gil...

February 20, 2024 | Tuesday | News
HUTCHMED & Inmagene Advance, License Drug Candidates IMG-007 and IMG-004

Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares representing approximately 7.5% of shares (fully diluted) in In...

February 02, 2024 | Friday | News
HUTCHMED Granted ELUNATE® Approval in Hong Kong for Metastatic Colorectal Cancer Treatment

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong&...

January 30, 2024 | Tuesday | News
China's RemeGen's RC88 earns FDA Fast Track, heralding new hope for ovarian cancer patients

RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently dev...

January 15, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close